Coeptis Therapeutics Holdings, Inc. announced the appointment of new directors to the Company's  board of directors following the completion of the previously announced business combination between Coeptis Therapeutics, Inc. The Board is now a seven-member board, four of whom are independent in compliance with the Nasdaq independence standards. The Board is now comprised of David Mehalick and Daniel Yerace (who have been board members with Coeptis Therapeutics, Inc. historically), Chris Calise (who was the Chief Financial Officer of the Company prior to the closing of the business combination), and newly added Board members Christopher Cochran, Philippe Deschamps, Tara DeSilva, PhD., and Gene Z. Salkind, MD.